- 작성일 : 20-10-12 10:31
- 조회 : 2,059회
October 12 – 16: 2020 Virtual Cell & Gene Meeting on the Mesa. Sunyoung Kim, D. Phil, Chief Executive Officer of Helixmith, will present an update on clinical development of Helixmith’s plasmid DNA product, Engensis, as well as an overview of other products in the company’s pipeline. Company presentations will be available to view on-demand throughout the entirety of the conference
Members of the company’s management and business development team will host one-on-one partnering meetings during the conference. To schedule a meeting, please use the Cell & Gene Meeting on the Mesa Partnering portal: https://www.meetingonthemesa.com/partnering/
October 26 – 29: BIO-Europe® Digital 2020. Sunyoung Kim, D. Phil, Chief Executive Officer of Helixmith, provided an on-demand company presentation on the clinical development of Helixmith’s plasmid DNA product, Engensis, as well as an overview of other products in the company’s pipeline. Registered attendees get access to on-demand content early – as early as September 21.
Members of the company’s management and business development teams will host one-on-one partnering meetings during the conference. To schedule a meeting, please use the BIO-Europe partnering portal at: https://informaconnect.com/bioeurope/partnering/.
About Chief Executive Officer, Sunyoung Kim, D. Phil.
Dr. Kim is the founder and CEO of Helixmith. Prior to founding Helixmith, Dr. Kim served as Professor at Seoul National University for over 20 years after serving as Assistant Professor at Harvard Medical School. Dr. Kim received his DPhil in Molecular Genetics at the University of Oxford, MS in Biochemical Engineering at MIT, MA in Microbiology and Molecular Genetics at Harvard University and held postdoctoral fellowships at Harvard Medical School and Whitehead Institute, MIT.
Helixmith's Engensis (VM202) is a gene therapy based on plasmid DNA. To date, more than 500 patients have been treated with Engensis across ten clinical trials in six different diseases and conditions. Data from clinical studies suggest that Engensis is well tolerated and has the potential to provide durable analgesic and/or symptomatic relief in a variety of disease settings. Beyond potentially alleviating pain, Engensis is designed to target the underlying cause of neuropathy through its predicted angiogenic and neuroregenerative properties. In 2018, the US FDA recognized the potential for Engensis to meet an unmet need for treatment in patients with diabetic peripheral neuropathy (DPN) by designating it as a Regenerative Medicine Advanced Therapy (RMAT), making it the first RMAT-designated gene therapy for a prevalent disease with over one million patients. This designation grants all the benefits afforded by the fast track and breakthrough designations, including priority review, in the development of Engensis for the DPN indication.
Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals to tackle previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease.
Helixmith clinical development and manufacturing activities are based in San Diego, California, where the company co-owns a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO also in San Diego. Genopis serves both Helixmith and external customers in need of plasmid DNA for medical purposes.
Jennifer Guzman, Senior Director, Medical Affairs Strategy
Phone: (760) 291-7245